Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

Selective norepinephrine reuptake inhibitors (sNRIs) provide an effective class of approved antipsychotics, whose inhibitory mechanism could facilitate the discovery of privileged scaffolds with enhanced drug efficacy. However, the crystal structure of human norepinephrine transporter (hNET) has not been determined yet and the inhibitory mechanism of sNRIs remains elusive. In this work, multiple computational methods were integrated to explore the inhibitory mechanism of approved sNRIs (atomoxetine, maprotiline, reboxetine and viloxazine), and 3 lines of evidences were provided to verify the calculation results. Consequently, a binding mode defined by interactions between three chemical moieties in sNRIs and eleven residues in hNET was identified as shared by approved sNRIs. In the meantime, binding modes of reboxetine’s enantiomers with hNET were compared. 6 key residues favoring the binding of (S, S)-reboxetine over that of (R, R)-reboxetine were discovered. This is the first study reporting that those 11 residues are the common determinants for the binding of approved sNRIs. The identified binding mode shed light on the inhibitory mechanism of approved sNRIs, which could help identify novel scaffolds with improved drug efficacy.

[1]  L. Çelik,et al.  Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. , 2008, Journal of the American Chemical Society.

[2]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[3]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[4]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[5]  The two enantiomers of citalopram bind to the human serotonin transporter in reversed orientations. , 2010 .

[6]  E. Gouaux,et al.  Structural basis for action by diverse antidepressants on biogenic amine transporters , 2013, Nature.

[7]  Eric Gouaux,et al.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters , 2007, Nature.

[8]  Jacob Andersen,et al.  Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. , 2009, Chemical communications.

[9]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[10]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[11]  S. Toubro,et al.  Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters , 2011, Proceedings of the National Academy of Sciences.

[12]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[13]  M. Millan,et al.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs , 2011, Neurotherapeutics.

[14]  L. Leventhal,et al.  1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors. , 2010, Journal of medicinal chemistry.

[15]  Eric Gouaux,et al.  X-ray structure of dopamine transporter elucidates antidepressant mechanism , 2013, Nature.

[16]  K. Trinkley,et al.  A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia , 2015, Journal of clinical pharmacy and therapeutics.

[17]  C. Zhan,et al.  Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. , 2009, The journal of physical chemistry. B.

[18]  Benjamin D. Madej,et al.  Lipid14: The Amber Lipid Force Field , 2014, Journal of chemical theory and computation.

[19]  Peer Bork,et al.  Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation , 2007, Bioinform..

[20]  Jeffery B. Klauda,et al.  CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes. , 2009, Biophysical journal.

[21]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[22]  S. Sinning,et al.  Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. , 2012, ACS chemical neuroscience.

[23]  Li Xie,et al.  Mechanism for alternating access in neurotransmitter transporters , 2008, Proceedings of the National Academy of Sciences.

[24]  P A Kollman,et al.  Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. , 2000, Journal of molecular biology.

[25]  A. Ravna,et al.  Substrate binding and translocation of the serotonin transporter studied by docking and molecular dynamics simulations , 2011, Journal of Molecular Modeling.

[26]  L. Çelik,et al.  Binding and Orientation of Tricyclic Antidepressants within the Central Substrate Site of the Human Serotonin Transporter* , 2009, The Journal of Biological Chemistry.

[27]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[28]  Sylvia Tippmann,et al.  Programming tools: Adventures with R , 2014, Nature.

[29]  Birgit Schiøtt,et al.  Monoamine transporters: insights from molecular dynamics simulations , 2015, Front. Pharmacol..

[30]  Wei Li,et al.  Triple reuptake inhibitors: a patent review (2006 – 2012) , 2014, Expert opinion on therapeutic patents.

[31]  D. Deecher,et al.  1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. , 2009, Journal of medicinal chemistry.

[32]  B. Schiøtt,et al.  Molecular Basis for Selective Serotonin Reuptake Inhibition by the Antidepressant Agent Fluoxetine (Prozac) , 2014, Molecular Pharmacology.

[33]  S. White,et al.  Recent advances in computer-aided drug design as applied to anti-influenza drug discovery. , 2014, Current topics in medicinal chemistry.

[34]  B. Kirtman,et al.  Efficient vector potential method for calculating electronic and nuclear response of infinite periodic systems to finite electric fields. , 2007, The Journal of chemical physics.

[35]  Huanxiang Liu,et al.  Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors , 2014, PloS one.

[36]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[37]  Jacob Andersen,et al.  Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter , 2015, Scientific Reports.

[38]  Turan Tufan,et al.  Corticotropin releasing factor up‐regulates the expression and function of norepinephrine transporter in SK‐N‐BE (2) M17 cells , 2015, Journal of neurochemistry.

[39]  K. Perry,et al.  Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder , 2002, Neuropsychopharmacology.

[40]  Harini Krishnamurthy,et al.  X-ray structures of LeuT in substrate-free outward-open and apo inward-open states , 2012, Nature.

[41]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[42]  Eric Gouaux,et al.  X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine , 2015, Nature Structural &Molecular Biology.

[43]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[44]  B. Ploeger,et al.  Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine , 2010, British journal of pharmacology.

[45]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[46]  R. A. Thompson,et al.  Software-aided structural elucidation in drug discovery. , 2015, Rapid communications in mass spectrometry : RCM.

[47]  Avner Schlessinger,et al.  Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET , 2011, Proceedings of the National Academy of Sciences.

[48]  G. Papakostas.  Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. , 2009, The Journal of clinical psychiatry.

[49]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[50]  B. Schiøtt,et al.  Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. , 2015, ACS chemical neuroscience.

[51]  P. Acton,et al.  2-(2-(dimethylaminomethyl)phenoxy)-5-iodophenylamine: an improved serotonin transporter imaging agent. , 2004, Journal of medicinal chemistry.

[52]  Jörg Weiser,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..

[53]  E. Wong,et al.  The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. , 2006, CNS drug reviews.

[54]  J. Javitch,et al.  A mechanism for intracellular release of Na+ by neurotransmitter/sodium symporters , 2014, Nature Structural &Molecular Biology.

[55]  M R Barer,et al.  Bacterial viability and culturability. , 1999, Advances in microbial physiology.

[56]  Anne Marie Jørgensen,et al.  Molecular Dynamics Simulations of Na+/Cl−‐Dependent Neurotransmitter Transporters in a Membrane‐Aqueous System , 2007, ChemMedChem.

[57]  T R Ten Have,et al.  Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease , 2010, Neurology.

[58]  A. Yan,et al.  Aurora-A kinase inhibitor scaffolds and binding modes. , 2011, Drug discovery today.

[59]  Ruben Abagyan,et al.  Identification of Novel Serotonin Transporter Compounds by Virtual Screening , 2014, J. Chem. Inf. Model..

[60]  Feng Zhu,et al.  Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. , 2016, Physical chemistry chemical physics : PCCP.

[61]  B. Schiøtt,et al.  Insights to ligand binding to the monoamine transporters—from homology modeling to LeuBAT and dDAT , 2015, Front. Pharmacol..

[62]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[63]  G. Salmon,et al.  Attention deficit hyperactivity disorder. , 2018, British journal of hospital medicine.

[64]  Hsuan-Liang Liu,et al.  Combining Structure‐Based Pharmacophore and In Silico Approaches to Discover Novel Selective Serotonin Reuptake Inhibitors , 2013, Chemical biology & drug design.

[65]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[66]  Eric Gouaux,et al.  A Competitive Inhibitor Traps LeuT in an Open-to-Out Conformation , 2008, Science.

[67]  Feng Zhu,et al.  Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. , 2015, Bio-medical materials and engineering.

[68]  A. Sandelin,et al.  Interaction of Antidepressants with the Serotonin and Norepinephrine Transporters , 2012, The Journal of Biological Chemistry.

[69]  Richard E. Carson,et al.  Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo , 2010, Biological Psychiatry.

[70]  Eric Gouaux,et al.  Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters , 2005, Nature.

[71]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[72]  F. Artigas.  Future directions for serotonin and antidepressants. , 2013, ACS chemical neuroscience.

[73]  L. Çelik,et al.  The two enantiomers of citalopram bind to the human serotonin transporter in reversed orientations. , 2010, Journal of the American Chemical Society.

[74]  T. Cheatham,et al.  Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.